Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Emasenyie Isikwei"'
Autor:
Kara L. Davis, Elizabeth Fox, Emasenyie Isikwei, Joel M. Reid, Xiaowei Liu, Charles G. Minard, Stephan Voss, Stacey L. Berg, Brenda J. Weigel, Crystal L. Mackall
Publikováno v:
Clinical Cancer Research. 28:5088-5097
Purpose: In many cancers, nivolumab in combination with ipilimumab improves response rates compared with either agent alone, but the combination has not been evaluated in childhood cancer. We conducted a phase I/II trial of nivolumab plus ipilimumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8867aef04e44414503ffd853978f8c24
https://doi.org/10.1158/1078-0432.ccr-22-2164
https://doi.org/10.1158/1078-0432.ccr-22-2164
Autor:
Crystal L. Mackall, Brenda J. Weigel, Stacey L. Berg, Stephan Voss, Charles G. Minard, Xiaowei Liu, Joel M. Reid, Emasenyie Isikwei, Elizabeth Fox, Kara L. Davis
Purpose:In many cancers, nivolumab in combination with ipilimumab improves response rates compared with either agent alone, but the combination has not been evaluated in childhood cancer. We conducted a phase I/II trial of nivolumab plus ipilimumab i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58255a46d495e7bb666c62ca9ccbbafd
https://doi.org/10.1158/1078-0432.c.6532749
https://doi.org/10.1158/1078-0432.c.6532749
Autor:
Crystal L. Mackall, Brenda J. Weigel, Stacey L. Berg, Stephan Voss, Charles G. Minard, Xiaowei Liu, Joel M. Reid, Emasenyie Isikwei, Elizabeth Fox, Kara L. Davis
Supplementary information
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::326581e72d684f6fd486fd9cbc06de60
https://doi.org/10.1158/1078-0432.22488516.v1
https://doi.org/10.1158/1078-0432.22488516.v1
Autor:
Crystal L. Mackall, Brenda J. Weigel, Stacey L. Berg, Stephan Voss, Charles G. Minard, Xiaowei Liu, Joel M. Reid, Emasenyie Isikwei, Elizabeth Fox, Kara L. Davis
Supplementary Figure 1. Nivolumab (A) and Ipilumumab (B) peak and trough concentrations in treatment cycles 1 – 4.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33b1deccf367dcd7733fd9bc08537f42
https://doi.org/10.1158/1078-0432.22488513.v1
https://doi.org/10.1158/1078-0432.22488513.v1
Autor:
Elizabeth S. Duke, Amy K. Barone, Somak Chatterjee, Pallavi S. Mishra-Kalyani, Yuan-Li Shen, Emasenyie Isikwei, Hong Zhao, Youwei Bi, Jiang Liu, Nam Atiqur Rahman, Emily Wearne, John K. Leighton, Maritsa Stephenson, Idara Ojofeitimi, Barbara Scepura, Abhilasha Nair, Richard Pazdur, Julia A. Beaver, Harpreet Singh
Publikováno v:
Clin Cancer Res
On September 17, 2021, the U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx™; Exelixis, Inc.) for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c0ec5bde23f247a822bb3ecd816099e
https://europepmc.org/articles/PMC9529996/
https://europepmc.org/articles/PMC9529996/
Autor:
Sameer A. Parikh, Caitlin M.G. McNulty, Brian Kabat, Avni Y. Joshi, Pragya Shrestha, Melissa R. Snyder, Susan L. Slager, Emasenyie Isikwei, Kari G. Rabe
Publikováno v:
Journal of Hematopathology. 13:221-229
Hypogammaglobinemia is a well-recognized complication in chronic lymphocytic leukemia (CLL); however, the risk factors that lead to this complication after treatment with anti-CD20 monoclonal antibodies are not well understood. Using the Mayo Clinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a2c3190a22ed23e450c772db9d76231
https://doi.org/10.1007/s12308-020-00417-5
https://doi.org/10.1007/s12308-020-00417-5
Autor:
Terzah M. Horton, Sharon Bergeron, Emasenyie Isikwei, Joel M. Reid, Charles G. Minard, Sarah Menig, Brenda J. Weigel, Elizabeth Fox, Xiaowei Liu, Katherine Tarlock, Todd M. Cooper
Publikováno v:
Journal of Clinical Oncology. 39:10018-10018
10018 Background: Outcomes for children with relapsed/refractory (R/R) AML and MDS are poor and new therapies are needed. Pevonedistat is an inhibitor of the NEDD-8 activating enzyme, a key regulator of the ubiquitin proteasome system that is respons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f72d1bacd420fb6b6d791bdf9d7db41c
https://doi.org/10.1200/jco.2021.39.15_suppl.10018
https://doi.org/10.1200/jco.2021.39.15_suppl.10018
Autor:
Sarah Injac, Stacey L. Berg, Elizabeth Fox, Jennifer Foster, Brenda J. Weigel, Charles G. Minard, Emasenyie Isikwei, Joel M. Reid, Xiaowei Liu
Publikováno v:
Journal of Clinical Oncology. 39:10019-10019
10019 Background: Pevonedistat (PEV), a first in class inhibitor of NEDD8 activating enzyme (NAE), prevents the activation of Cullin-RING ligases (CRL) necessary for proteasome mediated degradation of key regulatory proteins important in cell surviva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9fa198983f80c1f76cd02df2442e52cc
https://doi.org/10.1200/jco.2021.39.15_suppl.10019
https://doi.org/10.1200/jco.2021.39.15_suppl.10019